Cell kinetics of rat 9L brain tumors determined by double labeling with iodo- and bromodeoxyuridine
- PMID: 2366082
- DOI: 10.3171/jns.1990.73.2.0254
Cell kinetics of rat 9L brain tumors determined by double labeling with iodo- and bromodeoxyuridine
Abstract
Rats with 9L brain tumors received intraperitoneal injections of iododeoxyuridine (IUdR) and bromodeoxyuridine (BUdR) to estimate the duration of the deoxyribonucleic acid (DNA) synthesis phase (Ts) and the potential doubling time (Tp) of individual tumors. Different sequences and intervals (2 or 3 hours) of IUdR and BUdR administration were evaluated. After denaturation, tumor sections were reacted with Br-3, a monoclonal antibody that identifies only BUdR, and then were stained immunohistochemically by the avidinbiotin complex method. An antibody that recognizes both IUdR and BUdR, IU-4, was applied to the sections and identified by the alkaline phosphatase-antialkaline phosphatase method. Nuclei labeled only with IUdR stained blue, while those labeled with BUdR or with BUdR and IUdR stained brown. The fraction of cells that either left or entered the S-phase during the time between administration of IUdR and BUdR was measured to calculate Ts and Tp, assuming that the labeled cohort completed the DNA synthesis at a constant rate. The Ts was 8.8 hours (coefficient of variation (cv) = 0.05) and the Tp was 64.2 hours (cv = 0.08). The sequence and interval of administration of IUdR and BUdR had a minimal effect on Ts and Tp. In studies of 9L cells in monolayer culture, the Ts was 9.6 hours (cv = 0.08) and the TP was 30.6 hours (cv = 0.06). Double labeling with BUdR and IUdR allows the duration of the S-phase and potential doubling time of individual brain tumors to be estimated in situ from a single biopsy specimen.
Similar articles
-
[Proliferation kinetics of human brain tumors by in situ double labeling with bromodeoxyuridine and iododeoxyuridine].No To Shinkei. 1992 Sep;44(9):821-5. No To Shinkei. 1992. PMID: 1476811 Japanese.
-
Cell kinetic analysis of human brain tumors by in situ double labelling with bromodeoxyuridine and iododeoxyuridine.Int J Cancer. 1992 Jan 2;50(1):1-5. doi: 10.1002/ijc.2910500102. Int J Cancer. 1992. PMID: 1728598
-
Immunohistochemical double staining with immunogold-silver and alkaline phosphatase to identify nuclear markers of cellular proliferation.Biotech Histochem. 1993 Jan;68(1):17-9. doi: 10.3109/10520299309105571. Biotech Histochem. 1993. PMID: 8383543
-
Cell kinetics of glial tumors.Rev Neurol (Paris). 1992;148(6-7):396-401. Rev Neurol (Paris). 1992. PMID: 1448658 Review.
-
[A review of cell kinetic studies on brain tumors with special reference to anti-bromodeoxyuridine monoclonal antibody method].No Shinkei Geka. 1984 Aug;12(9):1007-18. No Shinkei Geka. 1984. PMID: 6390240 Review. Japanese.
Cited by
-
Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas.J Neurooncol. 1998 Jan;36(1):91-102. doi: 10.1023/a:1005805203044. J Neurooncol. 1998. PMID: 9525831 Review.
-
Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine.BMC Cancer. 2011 Apr 8;11:124. doi: 10.1186/1471-2407-11-124. BMC Cancer. 2011. PMID: 21477311 Free PMC article.
-
The application of 5-bromodeoxyuridine in the management of CNS tumors.J Neurooncol. 1994;20(1):81-95. doi: 10.1007/BF01057964. J Neurooncol. 1994. PMID: 7807187 Review.
-
Novel PKCeta is required to activate replicative functions of the major nonstructural protein NS1 of minute virus of mice.J Virol. 2003 Jul;77(14):8048-60. doi: 10.1128/jvi.77.14.8048-8060.2003. J Virol. 2003. PMID: 12829844 Free PMC article.
-
Boron neutron capture therapy: effects of split dose and overall treatment time.J Neurooncol. 2001 Apr;52(2):101-10. doi: 10.1023/a:1010689822493. J Neurooncol. 2001. PMID: 11508809
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical